• Je něco špatně v tomto záznamu ?

Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells

M. Jakubíková, J. Piťha, H. Marečková, M. Týblová, I. Nováková, J. Schutzner,

. 2015 ; 358 (1-2) : 101-6. [pub] 20150820

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16028268

BACKGROUND: Myasthenia gravis (MG) is the autoimmune disorder in which the thymus is considered the pathogenic organ. Thymectomy (TE) is a therapeutic option for MG and often ameliorates clinical symptoms. METHODS: We evaluated clinical features and outcomes after TE in patients without thymoma and the influence of TE with or without concomitant immunotherapy on the CD4(+)CD25(+) regulatory T cell subpopulation of lymphocytes in peripheral blood in defined followed groups of nonthymomatous MG patients. RESULTS: A total of 46 patients with generalized MG who underwent transsternal TE were identified. Neurologic outcomes after TE were favorable for the majority of patients mainly from the group treated with corticosteroids or combined immunosuppressive treatment. TEs with immunosuppressive treatment in MG patients were associated with increased percentages of CD4(+)CD25(+) cells (p<0.001). No significant change in the postoperative levels of CD4(+)CD25(+) cells was observed in thymectomized patients who preoperatively only received pyridostigmine. Also their clinical response to TE after 2 years of follow-up was worst of all followed groups. CONCLUSIONS: The exact mechanism by which TE ameliorates symptoms of MG is yet not clear. These observations indicate that increased percentages of CD4(+)CD25(+) T cells in MG may be related to disease stability and that TE and synergistic effect with concomitant, continuing immunotherapy augmented the proportion of CD4(+)CD25(+) T cells. On the basis of our observations TE alone is not enough to increase the number of circulating CD4(+)CD25(+) regulatory T cells and to establish complete stable remission.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028268
003      
CZ-PrNML
005      
20161025111037.0
007      
ta
008      
161005s2015 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jns.2015.08.029 $2 doi
024    7_
$a 10.1016/j.jns.2015.08.029 $2 doi
035    __
$a (PubMed)26320610
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jakubíková, Michala $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic. Electronic address: michala.jakubikova@vfn.cz.
245    10
$a Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells / $c M. Jakubíková, J. Piťha, H. Marečková, M. Týblová, I. Nováková, J. Schutzner,
520    9_
$a BACKGROUND: Myasthenia gravis (MG) is the autoimmune disorder in which the thymus is considered the pathogenic organ. Thymectomy (TE) is a therapeutic option for MG and often ameliorates clinical symptoms. METHODS: We evaluated clinical features and outcomes after TE in patients without thymoma and the influence of TE with or without concomitant immunotherapy on the CD4(+)CD25(+) regulatory T cell subpopulation of lymphocytes in peripheral blood in defined followed groups of nonthymomatous MG patients. RESULTS: A total of 46 patients with generalized MG who underwent transsternal TE were identified. Neurologic outcomes after TE were favorable for the majority of patients mainly from the group treated with corticosteroids or combined immunosuppressive treatment. TEs with immunosuppressive treatment in MG patients were associated with increased percentages of CD4(+)CD25(+) cells (p<0.001). No significant change in the postoperative levels of CD4(+)CD25(+) cells was observed in thymectomized patients who preoperatively only received pyridostigmine. Also their clinical response to TE after 2 years of follow-up was worst of all followed groups. CONCLUSIONS: The exact mechanism by which TE ameliorates symptoms of MG is yet not clear. These observations indicate that increased percentages of CD4(+)CD25(+) T cells in MG may be related to disease stability and that TE and synergistic effect with concomitant, continuing immunotherapy augmented the proportion of CD4(+)CD25(+) T cells. On the basis of our observations TE alone is not enough to increase the number of circulating CD4(+)CD25(+) regulatory T cells and to establish complete stable remission.
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    _2
$a dospělí $7 D000328
650    _2
$a antigeny CD4 $7 D015704
650    _2
$a počet CD4 lymfocytů $7 D018791
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a receptor interleukinu-2 - alfa-podjednotka $7 D053645
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myasthenia gravis $x krev $x farmakoterapie $x chirurgie $7 D009157
650    12
$a hodnocení výsledků zdravotní péče $7 D017063
650    12
$a regulační T-lymfocyty $7 D050378
650    _2
$a thymektomie $x metody $7 D013934
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Piťha, Jiří $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
700    1_
$a Marečková, Helena $u Department of Immunology and Microbiology, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
700    1_
$a Týblová, Michaela $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
700    1_
$a Nováková, Iveta $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
700    1_
$a Schutzner, Jan $u Third Department of Surgery, 1st Faculty of Medicine of Charles University and University Hospital Motol, Czech Republic.
773    0_
$w MED00003004 $t Journal of the neurological sciences $x 1878-5883 $g Roč. 358, č. 1-2 (2015), s. 101-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26320610 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161025111451 $b ABA008
999    __
$a ok $b bmc $g 1166582 $s 952898
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 358 $c 1-2 $d 101-6 $e 20150820 $i 1878-5883 $m Journal of the neurological sciences $n J Neurol Sci $x MED00003004
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...